Jacobs Levy Equity Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-45	Closed	-$49K	–	1077
2016 Q3	$49K	Hold	45	–	–	﹤0.01%	991
2016 Q2	$34K	Sell	45 -1	-2%	-$935	﹤0.01%	1130
2016 Q1	$32K	Sell	46 -34	-43%	-$29.5K	﹤0.01%	1075
2015 Q4	$79K	Buy	80 +53	+196%	+$70K	﹤0.01%	759
2015 Q3	$29K	Buy	+27	New	+$39.5K	﹤0.01%	796
2015 Q1	–	Sell	-17	Closed	-$17K	–	902
2014 Q4	$17K	Buy	+17	New	+$15.2K	﹤0.01%	805
2014 Q1	–	Sell	-27	Closed	-$61K	–	1027
2013 Q4	$61K	Buy	+27	New	+$61.8K	﹤0.01%	922
2013 Q3	–	Sell	-13	Closed	-$119K	–	1039
2013 Q2	$119K	Buy	+13	New	+$100K	﹤0.01%	928

Other funds holding ONCT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FHA

First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DAM

Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return

KLI

Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return

Jacobs Levy Equity Management's ONCT Position: Q4 2016 in Review

Jacobs Levy Equity Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2016, closing a stake of 45 shares — an estimated $49K sold.

Jacobs Levy Equity Management first reported a position in ONCT in Q2 2013 and held it in 8 quarters. The position peaked at $119K in Q2 2013. 21 funds tracked by Wall St. Rank hold ONCT as of Q4 2016.

Jacobs Levy Equity Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Jacobs Levy Equity Management sold 45 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $49K.
Jacobs Levy Equity Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
Jacobs Levy Equity Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $119K in Q2 2013.
21 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2016, filed 14 Feb 2017.